EyePoint's Drug for Age-Related Eye Disease Fails Late-Stage Trial, Shares Tank 70%

Eyepoint study results for vision treatment disappoint, but company still sees promise

The results of the study of the drug, Duravyu, could imperil biotech’s plans to seek regulatory approval in competitive field.

Why Is Ocular Therapeutix Stock Gaining Monday? - Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint plans a new trial and FDA submission for approval in 2027.

Ocular gains on EyePoint phase 3 wet AMD miss (OCUL:NASDAQ)

Ocular rises after EyePoint’s wet AMD trial for Duravyu failed to meet its primary goal. Read more here.

The Surprising Reason This Biotech Just Plummeted 71%

EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study.

EyePoint plummets on pivotal data for main drug

Though its drug missed the key goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.